Your session is about to expire
← Back to Search
Chemotherapy + Robotic Surgery for Throat Cancer (NECTORS Trial)
NECTORS Trial Summary
This trial is studying whether chemotherapy followed by surgery is more effective than the current standard of care for oropharyngeal cancer, which is chemo-radiotherapy.
NECTORS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowNECTORS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 32 Patients • NCT01301729NECTORS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My advanced cancer cannot be surgically removed without losing organ function.I currently have an infection.I have had head or neck cancer before, but not skin cancer.My throat cancer is p16 positive.I have not received any treatment for my condition.My cancer has not spread to distant parts of my body.My cancer has spread to distant parts of my body.I do not have any severe illnesses that could affect my treatment, and I can make informed decisions about my care.I am fit for surgery and my tumor can be completely removed through the mouth.My blood tests show normal white cell, platelet counts, and kidney function.I have not had cancer, except for specific skin cancers or early-stage cervical cancer, in the last 5 years.Doctors cannot reach my tumor through my mouth due to its location.I am older than 18 years.My tumor is P16 negative.I have 5 or more cancerous lymph nodes in my neck.I haven't had any cancer in the last 5 years, except for skin cancer.My cancer is at stage IVB according to AJCC-7.My cancer has spread outside the lymph node.I can care for myself and am up more than 50% of my waking hours.I have mild or no nerve damage symptoms.My cancer is at a specific advanced stage (Stage III or early Stage IV).I have previously been treated with Taxanes or Cisplatin.
- Group 1: Neoadjuvant chemotherapy and surgery
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Am I eligible to take part in this scientific experiment?
"Prospective participants in this trial must have a confirmed case of tonsillar cancer and fall between the ages 18-80. 60 patients are sought for recruitment."
Are there openings for participants in this investigation currently?
"Hosted on clinicaltrials.gov, this study is actively searching for participants; the trial was first posted in August of 2018 and updated just recently in April 2022."
What other investigations have been conducted with Docetaxel?
"Currently, 932 medical studies are investigating the efficacy of Docetaxel with 366 in Phase 3. Although most trials for this drug are based in Shanghai, there are over 61 thousand trial sites worldwide that offer it to patients."
Is the age range for this clinical examination limited to those over fifty?
"Participants must be between 18 and 80 in order to meet the qualifications of this clinical trial. According to research, there are 141 studies for minors under 18 years old and 3370 trials geared toward seniors over 65."
Has Docetaxel been authorized by the FDA for medical use?
"Docetaxel received a ranking of 2, as the Phase 2 trial has provided limited evidence for its safety but no data on efficacy."
How extensive is the participant pool of this clinical experiment?
"Affirmative. Clinicaltrials.gov's data affirms that this trial, which was initially listed on August 14th 2018, is actively seeking participants. Sixty individuals must be enrolled at a single location."
What maladies has Docetaxel been administered for historically?
"Docetaxel is routinely utilized to address end-of-life decisions, but also has the potential of treating brca1 gene, metastasis of neoplasms, and metastatic bladder cancer."
Share this study with friends
Copy Link
Messenger